Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.34B 1.16B 1.09B 996M 1.88B 128B 1.91B 12.74B 5B 63.79B 5.03B 4.92B 212B P/E 2026 *
-8.52x
P/E 2027 * -7.82x
Enterprise Value 1.34B 1.16B 1.09B 996M 1.88B 128B 1.91B 12.74B 5B 63.79B 5.03B 4.92B 212B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.16%
Yield 2026 *
-
Yield 2027 * -
08-04 ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-15 ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer MT
07-15 Oric Pharmaceuticals Initiates Himalayas-1 Global Phase 3 Trial in Patients with Mcrpc Previously Treated with Abiraterone CI
06-09 ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08:00 AM
05-05 ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-18 ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings CI
04-01 Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened MT
04-01 Top Premarket Decliners MT
04-01 Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating MT
04-01 ORIC Pharmaceuticals, Inc. - Special Call
04-01 ORIC Pharmaceuticals to Launch Phase 3 Trial of Prostate Cancer Drug Candidate, Shares Falter MT
04-01 ORIC Pharmaceuticals, Inc. Reports Selection Of Rinzimetostat RP3D In Combination With Darolutamide For Himalayas-1 Phase 3 Global Study With Dose Optimization Data Supporting Its Potential Best-In-Disease Profile CI
03-27 Oric Pharmaceuticals Reports Combination Dose Optimization Data From Phase 1b Trial Of Rinzimetostat In Patients With Metastatic Castration Resistant Prostate Cancer CI
1 week+14.63%
Current month+16.80%
1 month+11.08%
3 months+35.11%
6 months+29.82%
Current year+58.07%
1 week 10.45
Extreme 10.45
14.05
1 month 10.29
Extreme 10.29
14.05
Current year 7.23
Extreme 7.23
14.25
1 year 7.23
Extreme 7.23
14.93
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
26.7
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 07/05/2018
Director of Finance/CFO 52 01/09/2019
Chief Tech/Sci/R&D Officer - 18/08/2025
Director TitleAgeSince
Chairman 68 07/03/2018
Director/Board Member 47 07/05/2018
Director/Board Member 62 01/02/2020
Date Insider Type Main position Quantity % Market Cap.
24/07/26 Fiscal year

Founder

20,100 0.0194%
06/07/26 Sell

Founder

-300 0.0003%
24/02/26 Fiscal year

Chief Financial Officer

156,000 0.1602%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+14.63%+29.43%+68.58% 1.34B
-3.25%+12.81%+52.96%+88.86% 64.9B
+0.69%-2.81%+25.84%+68.41% 54.05B
-1.07%-1.89%-17.90%-14.36% 23.16B
+33.86%+28.54%+18.76%+502.77% 21.46B
+1.87%+5.08%+29.88%-7.94% 21.25B
-0.79%+0.54%+31.17%-25.84% 17.94B
-3.37%+19.44%+211.98%+369.13% 17.03B
+3.29%+2.09%+17.32%+586.49% 14.99B
-7.94%-5.66%+39.35%+157.52% 14.25B
Average +2.58%+4.49%+43.88%+179.36% 25.04B
Weighted average by Cap. +1.93%+3.70%+41.88%+146.59%

Financials

2026 *2027 *
Net sales - -
Net income -166M -144M -135M -123M -232M -15.78B -235M -1.57B -618M -7.88B -622M -608M -26.24B -196M -171M -160M -146M -276M -18.72B -279M -1.87B -733M -9.35B -738M -722M -31.13B
Net Debt - -
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
111
Date Price Change Volume
07/08/26 $12.93 0.00% 887,616
05/08/26 $12.93 -4.01% 2,138,163
04/08/26 $13.47 +27.08% 5,044,088
03/08/26 $10.60 -4.25% 2,460,217
31/07/26 $11.07 -4.90% 1,238,822
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
12.93USD
Average target price
20.85USD
Spread / Average Target
+61.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ORIC Stock